Cancer therapy is continues to evolve, with immune-oncology offering a new approach to treatment that holds significant promise. If cancer is detected, patients undergo a variety of tests of diagnosis, prognosis, and treatment decision-making. The need for multiple, diverse diagnostic approaches to guide treatment decision-making in oncology is not likely to change, and the emergence of groundbreaking immunotherapeutic drugs that work by stimulating the immune system to attack a tumour is only adding to the diagnostic complexity. Biomarker-based CDx are essential to guide treatment decisions and are a valuable tool to aid in patient selection for clinical testing of new I/O drugs.
Tissue-based biomarkers are proving to be invaluable for helping to stratify patients based on the immune context of a tumour and the patient-specific characteristics of the tumour microenvironment as well as interactions between tumour and immune cells and between a tumour and surrounding tissues. Tissue context biomarkers can capture this diversity and complexity, and biomarker-based CDx can drive individualized treatment decisions.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Association: International society for oncology, American association for cancer research, American Society of Clinical Oncology, BASO-the association for Cancer surgery, Cent Pour Sang La Vie, French National Cancer Institute.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
